ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Yseop Unveils Roadmap to One-Click Dossier: Accelerating Scalable, Compliant Regulatory Writing

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Yseop, the global leader in Generative AI for life sciences, today announced the next phase in delivering its One-Click Dossier vision, a scalable automation approach designed to streamline regulatory document generation and reduce time-to-submission. This will be formally presented during Yseop’s Innovation Theater session at the DIA Annual Meeting on June 17 in Washington, DC.

The One-Click Dossier streamlines the production of high quality regulatory documents, such as Clinical Study Reports (CSRs), patient narratives, summaries, and others in a fully automated workflow. By eliminating manual steps from data ingestion to draft creation, Yseop empowers life sciences teams to generate compliant, submission ready documents with significantly less effort and greater accuracy.

“Highly regulated industries like BioPharma often require weeks of manual work to produce compliant clinical documents,” said Emmanuel Walckenaer, CEO of Yseop. “With these core capabilities, we’re helping teams accelerate document creation today and move toward a future where regulatory submission could be as seamless as a single click.”

How Yseop is Building Toward One-Click Submissions

Built to meet eCTD standards, the One-Click Dossier addresses core industry challenges, including redundant copy-paste work, inconsistent data reuse, and long review cycles that delay submissions and time to market. By intelligently automating the authoring process, Yseop’s Copilot platform helps ensure traceability, version control, and compliance from the start.

Instead of manually stitching together data, writers now have a streamlined experience where documents are automatically assembled from verified inputs using context aware templates and AI-based data transformation. These capabilities are foundational to Yseop’s One-Click Dossier vision — enabling regulatory teams to work more efficiently today, while progressing toward a future where submission generation could be near-instant and fully automated.

The Four Building Blocks of One-Click Dossier

Documents created with One-Click Dossier are not static snapshots. They remain dynamically linked to source systems, allowing updates until final data lock, ensuring documents evolve in parallel with study data. This capability reduces rework, improves accuracy, and supports a more responsive regulatory workflow. Yseop’s end-to-end automation is powered by four tightly integrated components:

  • Direct Source Connectivity: Real-time integration with structured and unstructured data via Veeva Vault, Amazon S3, and other systems.
  • AI-Powered Data Processing: Intelligent extraction, structuring, and mapping of reusable content from diverse formats including ARDs and RTFs.
  • Automated Draft Generation: High-quality, submission-ready documents created in minutes, with full traceability from source to output.
  • Dynamic, Compliant Templates: Templates dynamically adapt to study context, such as therapeutic area, phase, and population, ensuring regulatory alignment and minimal rework.

“This isn’t just an enhancement, it redefines how pharma teams approach compliance and scale,” said Walckenaer. “We’re equipping writers with the tools they need to focus on science, not formatting.”

Trusted by the Industry’s Leaders

The next phase of One-Click Dossier builds on significant enterprise momentum for Yseop’s Copilot platform, which supports some of the world’s largest pharmaceutical organizations, including Eli Lilly and Novartis. Yseop’s recent growth highlights include:

  • Minimum 30–50% reduction in time spent on document creation, delivering faster turnaround for regulatory teams
  • 2–3 weeks acceleration in submission timelines, helping bring treatments to market more quickly
  • Study document volume has more than doubled year over year, showing deeper platform adoption across pharma teams.
  • Average of 27,000+ reports generated each month, underscoring the platform’s enterprise-grade scale and reliability

Yseop at the DIA Annual Meeting in Washington, DC
Yseop’s Innovation Theater presentation on June 17 at 11:45am in Innovation Theater #2 will showcase the capabilities behind One-Click Dossier and offer a look at the future of AI-powered regulatory operations. To experience One-Click Dossier firsthand, visit Yseop at Booth 609 or explore more at yseop.com.

About Yseop

Yseop is the leader in Generative AI for regulated industries, changing the way content automation solutions are delivered with a human-centric, AI platform. Yseop is reimagining the future of scientific writing to get medicine into the hands of those who need it faster. With a suite of industry-specific applications and technology that blends symbolic, machine learning, and LLM techniques, Yseop ensures that even the most demanding content automation tasks are met with ease, scalability and application security across the entire enterprise.

Media Contacts
FischTank PR
yseop@fischtankpr.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.